Sonoma pharmaceuticals reports first fiscal quarter 2024 financial results

Revenue increased 6% in the first fiscal quarter compared to the same period last year, excluding a one-time event last year margins remained consistent year over year in an inflationary period, excluding the one-time event sonoma continued to manage cash tightly, using only $0.3 million of cash in its first fiscal quarter boulder, co / accesswire / august 10, 2023 / sonoma pharmaceuticals, inc. (nasdaq:snoa),a global healthcare leader developing and producing stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended june 30, 2023. "we continued to grow our core business in the first fiscal quarter by adding new products, partners and territories while containing costs," said amy trombly, ceo of sonoma.
SNOA Ratings Summary
SNOA Quant Ranking